Jay Jiuping Ji
机构: National Cancer Institute
每年引用次数
引用次数
引用: 9,280
H-指数: 39
I10-指数 : 68
出版物: 141
Safety, tolerability, and antitumor activity of once-daily Wee-1 inhibitor AZD1775.
Naoko Takebe , Geraldine Helen O'Sullivan Coyne , Shivaani Kummar , Khanh Tu Do
Journal of Clinical Oncology 36 2587 -2587
2
2018
Phase I/Ib study of the PARP inhibitor olaparib (O) with carboplatin (C) in BRCA1/2 mutation carriers with breast or ovarian cancer (Br/OvCa) (NCT00647062).
Jung-min Lee , Christina M. Annunziata , John L. Hays , Anne M. Noonan
Journal of Clinical Oncology 31 2514 -2514
8
2013
Creating clinical target validation groups via quality assured transfer of robust clinical pharmacodynamic (PD) assays from the NCI: Clinical implementation of a PAR immunoassay in tumor biopsies.
Ralph E. Parchment , Robert J. Kinders , Jiuping Jay Ji , Apurva K. Srivastava
Journal of Clinical Oncology 31
2013
Using gamma-H2AX and H2AX quantitative ELISA for monitoring DNA damage induced by chemotherapeutic agents and irradiation exposure.
Jiuping Jay Ji , Yiping Zhang , Christophe E. Redon , Alice Chen
Journal of Clinical Oncology 33 2559 -2559
2015
Tumor genomic analysis for biomarker identification in a phase I trial of the Wee 1 inhibitor adavosertib (AZD1775).
Abdul Rafeh Naqash , Arjun Mittra , Geraldine Helen O'Sullivan Coyne , Li Chen
Journal of Clinical Oncology 38 3624 -3624
1
2020
Pharmacodynamic Response of the MET/HGF-Receptor to Small Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays
Apurva K. Srivastava , Melinda G. Hollingshead , Jennifer Weiner , Tony Navas
Clinical Cancer Research 22 ( 14) 3683 -3694
20
2016
A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.
Ivana Gojo , Jan H. Beumer , Keith W. Pratz , Michael A. McDevitt
Clinical Cancer Research 23 ( 3) 697 -706
31
2017
Proof of mechanism (POM) in the first-in-human trial of two novel indenoisoquinoline, non-camptothecin topoisomerase I (TOP1) inhibitors.
James H. Doroshow , Jiuping Jay Ji , Alice Chen , Deborah Allen
Journal of Clinical Oncology 30 3031 -3031
1
2012
Randomized trial of oral cyclophosphamide (C) with or without veliparib (V), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent BRCA-positive ovarian, or primary peritoneal or high-grade serous ovarian carcinoma.
Shivaani Kummar , Amit M. Oza , Gini F. Fleming , Daniel Sullivan
Journal of Clinical Oncology 30 5020 -5020
7
2012
Safety, pharmacodynamic, and clinical response evaluation of nilotinib and paclitaxel in adults with refractory solid tumors.
Sarah Shin , Geraldine Helen O'Sullivan Coyne , Shivaani Kummar , Murielle Hogu
Journal of Clinical Oncology 40 ( 16_suppl) 3026 -3026
2022
The root causes of pharmacodynamic assay failure
Katherine V. Ferry-Galow , Hala R. Makhlouf , Deborah F. Wilsker , Scott M. Lawrence
Seminars in Oncology 43 ( 4) 484 -491
8
2016
A validated assay for gamma-H2AX as a pharmacodynamic biomarker of response to DNA damage
Ralph Parchment , Yiping Zhang , Robert Kinders , Melinda Hollingshead
Cancer Research 67 4027 -4027
2
2007
Development and validation of a quantitative assay for H2AX in needle biopsies using topoisomerase I inhibitors
Robert J Kinders , Melinda G Hollingshead , Scott Lawrence , Jay Jiuping Ji
MOLECULAR CANCER THERAPEUTICS 6 ( 12) 3542S -3542S
2007
Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers
Christophe E. Redon , Asako J. Nakamura , Yong-Wei Zhang , Jiuping (Jay) Ji
Clinical Cancer Research 16 ( 18) 4532 -4542
196
2010
Implementation of Validated Pharmacodynamic Assays in Multiple Laboratories: Challenges, Successes, and Limitations
Robert Kinders , Kate Ferry-Galow , Lihua Wang , Apurva K. Srivastava
Clinical Cancer Research 20 ( 10) 2578 -2586
10
2014
Mutagenic mechanisms associated with perturbations of DNA precursor biosynthesis in phage T4
Jiuping Ji
2
1990
Codons 12 and 13 of H-ras Protooncogene Interrupt the Progression of DNA Synthesis Catalyzed by DNA Polymerase α
Lawrence A. Loeb , Jiuping Ji , Kandace J. Williams , Michael Fry
Cancer Research 53 ( 12) 2895 -2900
14
1993
Abstract #5456: Correlation between inhibition of the activity of poly(ADP-ribose) polymerase (PARP) in human peripheral blood mononuclear cells (PBMCs) and tumor biopsies following treatment with ABT-888, an inhibitor of PARP
Ralph Parchment , James Doroshow , Shivaani Kummar , Lamin Juwara
Cancer Research 69 5456 -5456
6
2009
SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma.
Rashmi Chugh , Karla V. Ballman , Lee J. Helman , Shreyaskumar Patel
Cancer 127 ( 8) 1301 -1310
1
2021
Identification of novel PARP inhibitors using a cell-based TDP1 inhibitory assay in a quantitative high-throughput screening platform
Junko Murai , Christophe Marchand , Sampada A. Shahane , Hongmao Sun
DNA Repair 21 177 -182
15
2014